Use of Chinese APIs leaves India vulnerable to shortages; Malaysian drugmaker shifts manufacturing

> A report says India's reliance on APIs from China leaves it vulnerable to drug shortages. Story

> Nigerian drugmaker May & Baker says its manufacturing operations have been approved by the World Health Organization as being cGMP compliant. Post

> The Chemical Company of Malaysia (CCM) intends to sell 6 pharmaceutical units it has in Malaysia, the Philippines and Singapore to its CCM Duopharma Biotech subsidiary for MYR133.3 million ($39 million), to increase the size of contracts it can accept. Report